BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

...smallest thing that gets people saying the sky...
BioCentury | Sep 10, 2020
Product Development

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

...or  β–amyloid, with no coordination.  “When the sky...
...to, so companies do it. When the sky...
BioCentury | May 28, 2020
Management Tracks

In new role as Flagship ‘CEO partner,’ Chouraqui to become Cellarity’s chief exec

...a construct we want to continue.” Flagship creates, incubates and invests in companies based on blue-sky...
BioCentury | Feb 8, 2020
Finance

Flagship adds asset-centric strategy to get more from its platform technologies

...Flagship Pioneering, whose investment strategy has always been blue-sky platform plays or bust, has decided to...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...for siRNA and oligos. These are real, accepted modalities and there is so much blue sky...
BioCentury | Nov 23, 2019
Politics, Policy & Law

Debating the fate of innovation

...drugs that would be created by biotechs. PhRMA and the companies it represents “insist the sky...
BioCentury | Nov 21, 2019
Financial News

Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene

...A led by Hikma Ventures, with participation from First Star Ventures, Pacific Health Ventures, Grey Sky...
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

...Programmed cell death 1 SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 TYRO3 (Sky...
BioCentury | Oct 11, 2019
Targets & Mechanisms

CAR Ts can move well beyond cancer, but will need to go allogeneic first

...of neurotoxicity and cytokine release syndrome to be mitigated. “The system is incredibly versatile. The sky...
BioCentury | Sep 21, 2019
Politics, Policy & Law

Congress won’t adopt Pelosi’s price controls, but it may revamp Medicare Part D

...support drug pricing legislation. To heed Trump’s call, he’ll need Democrats. “I don’t think the sky...
...American Enterprise Institute, told BioCentury. He called the changes “sensible,” adding: “I don’t think the sky...
Items per page:
1 - 10 of 119
BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

...smallest thing that gets people saying the sky...
BioCentury | Sep 10, 2020
Product Development

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

...or  β–amyloid, with no coordination.  “When the sky...
...to, so companies do it. When the sky...
BioCentury | May 28, 2020
Management Tracks

In new role as Flagship ‘CEO partner,’ Chouraqui to become Cellarity’s chief exec

...a construct we want to continue.” Flagship creates, incubates and invests in companies based on blue-sky...
BioCentury | Feb 8, 2020
Finance

Flagship adds asset-centric strategy to get more from its platform technologies

...Flagship Pioneering, whose investment strategy has always been blue-sky platform plays or bust, has decided to...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...for siRNA and oligos. These are real, accepted modalities and there is so much blue sky...
BioCentury | Nov 23, 2019
Politics, Policy & Law

Debating the fate of innovation

...drugs that would be created by biotechs. PhRMA and the companies it represents “insist the sky...
BioCentury | Nov 21, 2019
Financial News

Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene

...A led by Hikma Ventures, with participation from First Star Ventures, Pacific Health Ventures, Grey Sky...
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

...Programmed cell death 1 SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 TYRO3 (Sky...
BioCentury | Oct 11, 2019
Targets & Mechanisms

CAR Ts can move well beyond cancer, but will need to go allogeneic first

...of neurotoxicity and cytokine release syndrome to be mitigated. “The system is incredibly versatile. The sky...
BioCentury | Sep 21, 2019
Politics, Policy & Law

Congress won’t adopt Pelosi’s price controls, but it may revamp Medicare Part D

...support drug pricing legislation. To heed Trump’s call, he’ll need Democrats. “I don’t think the sky...
...American Enterprise Institute, told BioCentury. He called the changes “sensible,” adding: “I don’t think the sky...
Items per page:
1 - 10 of 119